Xenous (XITO) 10-Q 10 Feb 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Dec. 31, 2020	Feb. 08, 2021
Cover [Abstract]
Entity Registrant Name	XENOUS HOLDINGS, INC.
Entity Central Index Key	0001651932
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Small Business	true
Entity Shell Company	true
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Dec. 31, 2020
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Entity Common Stock Shares Outstanding		760,250,000
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	No

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Dec. 31, 2020	Mar. 31, 2020
Current Assets
Total Current Assets	$ 0	$ 0
TOTAL ASSETS	0	0
Current Liabilities
Accounts payable and accrued liabilities	16,874	6,130
Due to a related party	619,869	557,067
Total Current Liabilities	636,743	563,197
TOTAL LIABILITIES	636,743	563,197
STOCKHOLDERS' DEFICIT
Preferred stock, par value $0.001 per share, 10,000,000 shares authorized, no shares issued and outstanding	0	0
Common stock, par value $0.001 per share, 10,000,000,000 shares authorized, 760,250,000 shares issued and outstanding	760,250	760,250
Capital deficiency	(449,450)	(449,450)
Accumulated deficit	(947,543)	(873,997)
Total Stockholders' Deficit	(636,743)	(563,197)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 0	$ 0

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Mar. 31, 2020
STOCKHOLDERS' DEFICIT
Preferred stock, shares par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares par value	$ 0.001	$ 0.001
Common stock, shares authorized	10,000,000,000	10,000,000,000
Common stock, shares issued	760,250,000	760,250,000
Common stock, shares outstanding	760,250,000	760,250,000

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
OPERATING EXPENSES
General and administrative	$ 145	$ 1,072	$ 11,558	$ 7,361
Professional fees	19,488	13,164	61,988	42,414
Operating expense	19,633	14,236	73,546	49,775
OPERATING LOSS	(19,633)	(14,236)	(73,546)	(49,775)
OTHER EXPENSE
Interest expense	0	(2,144)	0	(6,407)
TOTAL OTHER EXPENSE	0	(2,144)	0	(6,407)
NET LOSS	$ (19,633)	$ (16,380)	$ (73,546)	$ (56,182)
Basic and Diluted Loss per Common Share	$ 0	$ 0	$ 0	$ 0
Basic and Diluted Weighted Average Number of Common Shares	760,250,000	760,250,000	760,250,000	760,250,000

Condensed Statements of Changes

Condensed Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Total	Common Stock	Capital Deficiency	Accumulated Deficit
Balance, shares at Mar. 31, 2019		760,250,000
Balance, amount at Mar. 31, 2019	$ (499,278)	$ 760,250	$ (449,450)	$ (810,078)
Net loss	(17,764)	$ 0	0	(17,764)
Balance, shares at Jun. 30, 2019		760,250,000
Balance, amount at Jun. 30, 2019	(517,042)	$ 760,250	(449,450)	(827,842)
Balance, shares at Mar. 31, 2019		760,250,000
Balance, amount at Mar. 31, 2019	(499,278)	$ 760,250	(449,450)	(810,078)
Net loss	(56,182)
Balance, shares at Dec. 31, 2019		760,250,000
Balance, amount at Dec. 31, 2019	(555,460)	$ 760,250	(449,450)	(866,260)
Balance, shares at Jun. 30, 2019		760,250,000
Balance, amount at Jun. 30, 2019	(517,042)	$ 760,250	(449,450)	(827,842)
Net loss	(22,038)	$ 0	0	(22,038)
Balance, shares at Sep. 30, 2019		760,250,000
Balance, amount at Sep. 30, 2019	(539,080)	$ 760,250	(449,450)	(849,880)
Net loss	(16,380)	$ 0	0	(16,380)
Balance, shares at Dec. 31, 2019		760,250,000
Balance, amount at Dec. 31, 2019	(555,460)	$ 760,250	(449,450)	(866,260)
Balance, shares at Mar. 31, 2020		760,250,000
Balance, amount at Mar. 31, 2020	(563,197)	$ 760,250	(449,450)	(873,997)
Net loss	(43,269)	$ 0	0	(43,269)
Balance, shares at Jun. 30, 2020		760,250,000
Balance, amount at Jun. 30, 2020	(606,466)	$ 760,250	(449,450)	(917,266)
Balance, shares at Mar. 31, 2020		760,250,000
Balance, amount at Mar. 31, 2020	(563,197)	$ 760,250	(449,450)	(873,997)
Net loss	(73,546)
Balance, shares at Dec. 31, 2020		760,250,000
Balance, amount at Dec. 31, 2020	(636,743)	$ 760,250	(449,450)	(947,543)
Balance, shares at Jun. 30, 2020		760,250,000
Balance, amount at Jun. 30, 2020	(606,466)	$ 760,250	(449,450)	(917,266)
Net loss	(10,644)	$ 0	0	(10,644)
Balance, shares at Sep. 30, 2020		760,250,000
Balance, amount at Sep. 30, 2020	(617,110)	$ 760,250	(449,450)	(927,910)
Net loss	(19,633)	$ 0	0	(19,633)
Balance, shares at Dec. 31, 2020		760,250,000
Balance, amount at Dec. 31, 2020	$ (636,743)	$ 760,250	$ (449,450)	$ (947,543)

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (73,546)	$ (56,182)
Changes in operating assets and liabilities:
Prepaid expenses	0	7,000
Accounts payable and accrued liabilities	10,744	(2,586)
Accrued interest, related party	0	6,407
Net cash used in operating activities	(62,802)	(45,361)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from related party advances	62,802	45,361
Net cash provided by financing activities	62,802	45,361
Net changes in cash and cash equivalents	0	0
Cash and cash equivalents - beginning of period	0	0
Cash and cash equivalents - end of period	0	0
Supplemental Cash Flow Disclosures
Cash paid for interest	0	0
Cash paid for income taxes	$ 0	$ 0

NATURE OF BUSINESS AND CONTINUA

NATURE OF BUSINESS AND CONTINUANCE OF OPERATIONS	9 Months Ended
	Dec. 31, 2020
NATURE OF BUSINESS AND CONTINUANCE OF OPERATIONS
NOTE 1 - NATURE OF BUSINESS AND CONTINUANCE OF OPERATIONS	Xenous Holdings, Inc. (the “Company”) was incorporated on May 20, 1980 as Dayne Weiss and Associates, Inc. under the laws of the State of Utah. On December 19, 2014, the Company completed a change of domicile merger with Concept Holding Corp., a Nevada corporation, which became the surviving entity. On July 21, 2017, the Board of Directors of the Company elected to file Articles of Merger with the Nevada SOS whereby it would enter into a statutory merger with its wholly-owned subsidiary, M101 Corp., a Nevada corporation, pursuant to Nevada Revised Statutes 92A.200, et seq. The effect of such merger is the Company is the surviving entity and changed its name to “M101 Corp.” The merger took effect on August 14, 2017. On November 2, 2019, a majority of shareholders approved a resolution to change the name of the Company to Xenous Holdings, Inc. On November 19, 2019, the Company received notice that the Secretary of State of Nevada accepted the Company’s Certificate of Amendment to its Articles of Incorporation to change the name of the Company to Xenous Holdings, Inc. The Company currently has no business operations.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Dec. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Basis of Presentation The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine months ended December 31, 2020 are not necessarily indicative of the results that may be expected for the year ending March 31, 2021. The notes to the unaudited financial statements are condensed, as disclosures that would substantially duplicate the disclosures contained in the audited financial statements for fiscal year 2020 have been omitted. This report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended March 31, 2020 included in the Company’s Form 10-K as filed with the Securities and Exchange Commission on July 14, 2020. Use of Estimates The Company prepares its financial statements in conformity with “GAAP,” which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Financial Instruments The Company’s financial instruments consist primarily of accounts payable and debts. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments. Related Parties We follow ASC 850, “Related Party Disclosures,” COVID-19 In early 2020, the World Health Organization declared the rapidly spreading coronavirus disease (COVID-19) outbreak a pandemic. This pandemic has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. The Company considered the impact of COVID-19 on the assumptions and estimates used and determined that there were no material adverse impacts on the Company’s results of operations and financial position at December 31, 2020. The full extent of the future impacts of COVID-19 on the Company’s operations is uncertain. A prolonged outbreak could have a material adverse impact on financial results and business operations of the Company in the future. The Company is not 10 may Recently Issued Accounting Pronouncements Management has considered all recent accounting pronouncements issued and believes that these recent pronouncements will not have a material effect on the Company’s financial statements

GOING CONCERN

GOING CONCERN	9 Months Ended
	Dec. 31, 2020
GOING CONCERN
NOTE 3 - GOING CONCERN	The Company has not yet generated any revenue since its inception and has an operating loss and net loss of $73,546 for the nine months ended December 31, 2020. As of December 31, 2020, the Company has accumulated deficit of $947,543, and negative working capital of $636,743. The Company’s continuation as a going concern is dependent on its ability to execute its operation plan to generate sufficient cash flows from operations to meet its obligations and/or obtaining additional financing from its shareholders or other sources, as may be required. There can be no assurance that the necessary debt or equity financing will be available or will be available on terms acceptable to the Company. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern; however, the above conditions raise substantial doubt about the Company’s ability to do so. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern. While we believe in the viability of our strategy to generate sufficient revenues in the future and in our ability to raise additional funds, there can be no assurances to that effect.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Dec. 31, 2020
RELATED PARTY TRANSACTIONS
NOTE 4 - RELATED PARTY TRANSACTIONS	Due to Related Party During nine months ended December 31, 2020 and 2019, Smartex Investment Ltd., the majority shareholder of the Company which is holding 82% of the Company’s common shares, advanced $62,802 and $45,361, respectively, to the Company for operating expenses. As of December 31, 2020 and March 31, 2020, total amount due to Smartex Investment Ltd. was $619,869 and $557,067, respectively. The loan is non-interest bearing and due on demand.

SHARE CAPITAL

SHARE CAPITAL	9 Months Ended
	Dec. 31, 2020
SHARE CAPITAL
NOTE 5 - SHARE CAPITAL	Preferred Stock The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.001 per share. As of December 31, 2020 and March 31, 2020, no preferred shares have been issued. Common Stock The Company is authorized to issue 10,000,000,000 shares of common stock with a par value of $0.001 per share. There were no stock issuances during the nine months ended December 31, 2020 or 2019. As of December 31, 2020 and March 31, 2020, the Company had 760,250,000 shares of common stock issued and outstanding.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Dec. 31, 2020
SUBSEQUENT EVENTS
NOTE 6 - SUBSEQUENT EVENTS	Management has evaluated subsequent events through the date these financial statements were issued. Based on our evaluation, no events have occurred that require disclosure.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Dec. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation	The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine months ended December 31, 2020 are not necessarily indicative of the results that may be expected for the year ending March 31, 2021. The notes to the unaudited financial statements are condensed, as disclosures that would substantially duplicate the disclosures contained in the audited financial statements for fiscal year 2020 have been omitted. This report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended March 31, 2020 included in the Company’s Form 10-K as filed with the Securities and Exchange Commission on July 14, 2020.
Use of Estimates	The Company prepares its financial statements in conformity with “GAAP,” which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Financial Instruments	The Company’s financial instruments consist primarily of accounts payable and debts. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.
Related Parties	We follow ASC 850, “Related Party Disclosures,”
COVID-19	In early 2020, the World Health Organization declared the rapidly spreading coronavirus disease (COVID-19) outbreak a pandemic. This pandemic has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. The Company considered the impact of COVID-19 on the assumptions and estimates used and determined that there were no material adverse impacts on the Company’s results of operations and financial position at December 31, 2020. The full extent of the future impacts of COVID-19 on the Company’s operations is uncertain. A prolonged outbreak could have a material adverse impact on financial results and business operations of the Company in the future. The Company is not 10 may
Recently Issued Accounting Pronouncements	Management has considered all recent accounting pronouncements issued and believes that these recent pronouncements will not have a material effect on the Company’s financial statements

NATURE OF BUSINESS AND CONTIN_2

NATURE OF BUSINESS AND CONTINUANCE OF OPERATIONS (Detail Narrative)	Nov. 02, 2019
NATURE OF BUSINESS AND CONTINUANCE OF OPERATIONS
Name change of company description	A majority of shareholders approved a resolution to change the name of the Company to Xenous Holdings, Inc. (the Company)

GOING CONCERN (Detail Narrative

GOING CONCERN (Detail Narrative) - USD ($)	3 Months Ended						9 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2020
GOING CONCERN
Accumulated deficit	$ (947,543)						$ (947,543)		$ (873,997)
Net loss	(19,633)	$ (10,644)	$ (43,269)	$ (16,380)	$ (22,038)	$ (17,764)	(73,546)	$ (56,182)
OPERATING LOSS	(19,633)			$ (14,236)			(73,546)	$ (49,775)
Working capital deficit	$ (636,743)						$ (636,743)

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2020
Proceeds from related party advances	$ 62,802	$ 45,361
Smartex Investment Ltd [Member]
Proceeds from related party advances	62,802	$ 45,361
Due to related party	$ 619,869		$ 557,067
Ownership percentage	82.00%

SHARE CAPITAL (Details Narrativ

SHARE CAPITAL (Details Narrative) - $ / shares	Dec. 31, 2020	Mar. 31, 2020
SHARE CAPITAL (Details Narrative)
Preferred stock, par value, per share in dollars	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value in dollars	$ 0.001	$ 0.001
Common stock, shares authorized	10,000,000,000	10,000,000,000
Common stock, shares issued	760,250,000	760,250,000
Common stock, shares outstanding	760,250,000	760,250,000